

**Cell Reports, Volume 8**

**Supplemental Information**

**Modulation of cAMP and Ras Signaling Pathways**

**Improves Distinct Behavioral Deficits**


**in a Zebrafish Model of Neurofibromatosis Type 1**

**Marc A. Wolman, Eric D. de Groh, Sean M. McBride, Thomas A. Jongens, Michael  
Granato, and Jonathan A. Epstein**

## SUPPLEMENTAL INFORMATION


### Modulation of cAMP and Ras Signaling Pathways Improves Distinct Behavioral Deficits in a Zebrafish Model of Neurofibromatosis Type 1

Wolman et al.




**Figure S1, Related to Figure 2. cAMP Signaling Mediates *nf1*-Dependent Acoustic Learning**

(A) Schematic representation of acoustic learning assay. (B-D) Mean habituation percentage to repeated acoustic stimulation ( $n = 12\text{-}32$  larvae per genotype/treatment). # $P < 0.001$  versus DMSO-treated wild-type larvae. \* $P < 0.01$ , \*\* $P < 0.001$  versus DMSO-treated *nf1a*<sup>-/-</sup>; *nf1b*<sup>-/-</sup> larvae. One-way ANOVA. Error bars denote SEM.



**Figure S2, Related to Figure 1. Enhanced cAMP Signaling Does Not Improve Memory Recall in *nf1* Mutants**

Mean O-bend latency change 1 h after spaced training (test) versus untrained controls ( $n = 35$  to 66 O-bend maneuvers per genotype/treatment).  $\#P < 0.001$  versus DMSO-treated wild-type larvae. One-way ANOVA. Error bars denote SEM.



**Figure S3, Related to Figures 1-3. Pharmacologic Specificity of Reagents Used in Behavioral Assays**

Wild-type larvae were treated with DMSO or small molecules (at the concentrations noted) for 30 min, fixed, and sectioned for immunohistochemistry with (A-F) anti-phospho-(Ser/Thr) PKA substrate antibody or (G-L) anti-phospho-ERK antibody. Longitudinal sections through the brain (arrow) and eyes are shown. Scale bar represents 100 μM.

**Movie S1, Related to Figure 1. Zebrafish Larva Performs O-Bend Response to Dark Flash Stimulus**